Search

everythinglearnresearchcommunity

for

Search:↓

Some breast cancer chemotherapy can cause permanent hair loss.

Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

A woman's hair loss was initially mistaken for a common hair loss condition but was later found to be caused by breast cancer cells in her scalp.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.

The document concludes that modern photo stories help represent and challenge how breast cancer affects women's identities and societal norms.

Finasteride use may increase the risk of male breast cancer.

Finasteride use is not clearly linked to an increased risk of male breast cancer.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.

Some breast cancer treatments, like taxanes, can cause long-term hair loss.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

Understanding breast cancer requires considering both medical advancements and social influences.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.

Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.

X-ray diffraction of hair might help detect breast cancer non-invasively.

Minoxidil in breast milk may harm nursing infants.

Xiaoaiping reduces chemotherapy side effects and improves quality of life for breast cancer patients.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.